412 related articles for article (PubMed ID: 31214203)
21. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors.
Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX
Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329
[TBL] [Abstract][Full Text] [Related]
22. Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development.
Bae WY; Choi JS; Kim JE; Park C; Jeong JW
Oncotarget; 2016 Jul; 7(30):47232-47241. PubMed ID: 27323807
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression.
Littlepage LE; Sternlicht MD; Rougier N; Phillips J; Gallo E; Yu Y; Williams K; Brenot A; Gordon JI; Werb Z
Cancer Res; 2010 Mar; 70(6):2224-34. PubMed ID: 20215503
[TBL] [Abstract][Full Text] [Related]
24. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases: new routes to the use of MT1-MMP as a therapeutic target in angiogenesis-related disease.
Arroyo AG; Genís L; Gonzalo P; Matías-Román S; Pollán A; Gálvez BG
Curr Pharm Des; 2007; 13(17):1787-802. PubMed ID: 17584108
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion.
Kaliski A; Maggiorella L; Cengel KA; Mathe D; Rouffiac V; Opolon P; Lassau N; Bourhis J; Deutsch E
Mol Cancer Ther; 2005 Nov; 4(11):1717-28. PubMed ID: 16275993
[TBL] [Abstract][Full Text] [Related]
27. The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.
Fields GB
Cells; 2019 Aug; 8(9):. PubMed ID: 31461880
[TBL] [Abstract][Full Text] [Related]
28. Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition.
Lauer-Fields JL; Whitehead JK; Li S; Hammer RP; Brew K; Fields GB
J Biol Chem; 2008 Jul; 283(29):20087-95. PubMed ID: 18499673
[TBL] [Abstract][Full Text] [Related]
29. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase 2 and membrane type 1 matrix metalloproteinase co-regulate axonal outgrowth of mouse retinal ganglion cells.
Gaublomme D; Buyens T; De Groef L; Stakenborg M; Janssens E; Ingvarsen S; Porse A; Behrendt N; Moons L
J Neurochem; 2014 Jun; 129(6):966-79. PubMed ID: 24611815
[TBL] [Abstract][Full Text] [Related]
31. Engineered s-Triazine-Based Dendrimer-Honokiol Conjugates as Targeted MMP-2/9 Inhibitors for Halting Hepatocellular Carcinoma.
Khalil HH; Osman HA; Teleb M; Darwish AI; Abu-Serie MM; Khattab SN; Haiba NS
ChemMedChem; 2021 Dec; 16(24):3701-3719. PubMed ID: 34547831
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis.
Friehs I; Margossian RE; Moran AM; Cao-Danh H; Moses MA; del Nido PJ
Basic Res Cardiol; 2006 May; 101(3):204-13. PubMed ID: 16369727
[TBL] [Abstract][Full Text] [Related]
33. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis.
Oh J; Takahashi R; Kondo S; Mizoguchi A; Adachi E; Sasahara RM; Nishimura S; Imamura Y; Kitayama H; Alexander DB; Ide C; Horan TP; Arakawa T; Yoshida H; Nishikawa S; Itoh Y; Seiki M; Itohara S; Takahashi C; Noda M
Cell; 2001 Dec; 107(6):789-800. PubMed ID: 11747814
[TBL] [Abstract][Full Text] [Related]
34. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
35. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
Piperigkou Z; Manou D; Karamanou K; Theocharis AD
Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinases: new directions toward inhibition in the fight against cancers.
King SE
Future Med Chem; 2016; 8(3):297-309. PubMed ID: 26910530
[TBL] [Abstract][Full Text] [Related]
37. Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.
Sudhakar YA; Verma RK; Pawar SC
Sci Rep; 2014 Mar; 4():4136. PubMed ID: 24670518
[TBL] [Abstract][Full Text] [Related]
38. N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.
Nuti E; Cantelmo AR; Gallo C; Bruno A; Bassani B; Camodeca C; Tuccinardi T; Vera L; Orlandini E; Nencetti S; Stura EA; Martinelli A; Dive V; Albini A; Rossello A
J Med Chem; 2015 Sep; 58(18):7224-40. PubMed ID: 26263024
[TBL] [Abstract][Full Text] [Related]
39. Chemically synthesized matrix metalloproteinase and angiogenesis-inhibiting peptides as anticancer agents.
Hu J; Yan M; Pu C; Wang J; Van den Steen PE; Opdenakker G; Xu H
Anticancer Agents Med Chem; 2014 Mar; 14(3):483-94. PubMed ID: 24533654
[TBL] [Abstract][Full Text] [Related]
40. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
